Literature DB >> 19570652

Serotonergic hyperinnervation and effective serotonin blockade in an FGF receptor developmental model of psychosis.

Ilona Klejbor1, Aaron Kucinski, Scott R Wersinger, Thomas Corso, Jan H Spodnik, Jerzy Dziewiatkowski, Janusz Moryś, Renae A Hesse, Kenner C Rice, Robert Miletich, Ewa K Stachowiak, Michal K Stachowiak.   

Abstract

The role of fibroblast growth factor receptors (FGFR) in normal brain development has been well-documented in transgenic and knock-out mouse models. Changes in FGF and its receptors have also been observed in schizophrenia and related developmental disorders. The current study examines a transgenic th(tk-)/th(tk-) mouse model with FGF receptor signaling disruption targeted to dopamine (DA) neurons, resulting in neurodevelopmental, anatomical, and biochemical alterations similar to those observed in human schizophrenia. We show in th(tk-)/th(tk-) mice that hypoplastic development of DA systems induces serotonergic hyperinnervation of midbrain DA nuclei, demonstrating the co-developmental relationship between DA and 5-HT systems. Behaviorally, th(tk-)/th(tk-) mice displayed impaired sensory gaiting and reduced social interactions correctable by atypical antipsychotics (AAPD) and a specific 5-HT2A antagonist, M100907. The adult onset of neurochemical and behavioral deficits was consistent with the postpubertal time course of psychotic symptoms in schizophrenia and related disorders. The spectrum of abnormalities observed in th(tk-)/th(tk-) mice and the ability of AAPD to correct the behavioral deficits consistent with human psychosis suggests that midbrain 5-HT2A-controlling systems are important loci of therapeutic action. These results may provide further insight into the complex multi-neurotransmitter etiology of neurodevelopmental diseases such autism, bipolar disorder, Asperger's Syndrome and schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19570652      PMCID: PMC4681496          DOI: 10.1016/j.schres.2009.06.006

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  75 in total

1.  Open-label risperidone for Asperger's disorder: negative symptom spectrum response.

Authors:  Jeffrey L Rausch; Elizabeth L Sirota; Donna L Londino; Maria E Johnson; Benjamin M Carr; Renu Bhatia; Stephen Miller
Journal:  J Clin Psychiatry       Date:  2005-12       Impact factor: 4.384

Review 2.  The physiological and pharmacological role of basic fibroblast growth factor in the dopaminergic nigrostriatal system.

Authors:  Claudia Grothe; Marco Timmer
Journal:  Brain Res Rev       Date:  2007-01-16

Review 3.  Serotonergic basis of antipsychotic drug effects in schizophrenia.

Authors:  J A Lieberman; R B Mailman; G Duncan; L Sikich; M Chakos; D E Nichols; J E Kraus
Journal:  Biol Psychiatry       Date:  1998-12-01       Impact factor: 13.382

4.  Targeting novel integrative nuclear FGFR1 signaling by nanoparticle-mediated gene transfer stimulates neurogenesis in the adult brain.

Authors:  Ewa K Stachowiak; Indrajit Roy; Yu-Wei Lee; Mariolina Capacchietti; John M Aletta; Paras N Prasad; Michal K Stachowiak
Journal:  Integr Biol (Camb)       Date:  2009-05-08       Impact factor: 2.192

5.  Comparison of quetiapine and risperidone in the treatment of schizophrenia: A randomized, double-blind, flexible-dose, 8-week study.

Authors:  Kate X Zhong; Dennis E Sweitzer; Robert M Hamer; Jeffrey A Lieberman
Journal:  J Clin Psychiatry       Date:  2006-07       Impact factor: 4.384

6.  Synaptic contacts in schizophrenia: studies using immunocytochemical identification of dopaminergic neurons.

Authors:  N S Kolomeets; N A Uranova
Journal:  Neurosci Behav Physiol       Date:  1999 Mar-Apr

7.  Fgfr2 and Fgfr3 are not required for patterning and maintenance of the midbrain and anterior hindbrain.

Authors:  Alexandra A Blak; Thorsten Naserke; Jonna Saarimäki-Vire; Paula Peltopuro; Mario Giraldo-Velasquez; Daniela M Vogt Weisenhorn; Nilima Prakash; Michael Sendtner; Juha Partanen; Wolfgang Wurst
Journal:  Dev Biol       Date:  2006-11-10       Impact factor: 3.582

8.  cAMP-induced differentiation of human neuronal progenitor cells is mediated by nuclear fibroblast growth factor receptor-1 (FGFR1).

Authors:  E K Stachowiak; X Fang; J Myers; S Dunham; M K Stachowiak
Journal:  J Neurochem       Date:  2003-03       Impact factor: 5.372

9.  Nuclear trafficking of FGFR1: a role for the transmembrane domain.

Authors:  Jason M Myers; Gabriel G Martins; Jacek Ostrowski; Michal K Stachowiak
Journal:  J Cell Biochem       Date:  2003-04-15       Impact factor: 4.429

10.  Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning.

Authors:  Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

View more
  10 in total

1.  Neuroanatomic and behavioral traits for autistic disorders in age-specific restricted index selection mice.

Authors:  L Meng; L Lu; K M Murphy; C M Yuede; J M Cheverud; J G Csernansky; H Dong
Journal:  Neuroscience       Date:  2011-05-26       Impact factor: 3.590

2.  Activation of developmental nuclear fibroblast growth factor receptor 1 signaling and neurogenesis in adult brain by α7 nicotinic receptor agonist.

Authors:  Sridhar T Narla; Ilona Klejbor; Barbara Birkaya; Yu-Wei Lee; Janusz Morys; Ewa K Stachowiak; Dorota Prokop; Merouane Bencherif; Michal K Stachowiak
Journal:  Stem Cells Transl Med       Date:  2013-09-06       Impact factor: 6.940

Review 3.  Sensory processing in autism spectrum disorders and Fragile X syndrome-From the clinic to animal models.

Authors:  D Sinclair; B Oranje; K A Razak; S J Siegel; S Schmid
Journal:  Neurosci Biobehav Rev       Date:  2016-05-24       Impact factor: 8.989

Review 4.  The molecular basis of cognitive deficits in pervasive developmental disorders.

Authors:  Aditi Bhattacharya; Eric Klann
Journal:  Learn Mem       Date:  2012-08-16       Impact factor: 2.460

5.  Fibroblast growth factor deficiencies impact anxiety-like behavior and the serotonergic system.

Authors:  Leah R Brooks; Courtney L Enix; Samuel C Rich; Jinno A Magno; Christopher A Lowry; Pei-San Tsai
Journal:  Behav Brain Res       Date:  2014-02-07       Impact factor: 3.332

6.  TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.

Authors:  T A Hauser; A Kucinski; K G Jordan; G J Gatto; S R Wersinger; R A Hesse; E K Stachowiak; M K Stachowiak; R L Papke; P M Lippiello; M Bencherif
Journal:  Biochem Pharmacol       Date:  2009-05-29       Impact factor: 5.858

7.  Dopamine neurons in the ventral tegmental area: an autopsy case of disorganized type of schizophrenia.

Authors:  Keiko Ikemoto; Tatsuro Oda; Akiyoshi Nishimura; Katsuji Nishi
Journal:  Case Rep Neurol Med       Date:  2011-09-22

8.  Copy number variants in extended autism spectrum disorder families reveal candidates potentially involved in autism risk.

Authors:  Daria Salyakina; Holly N Cukier; Joycelyn M Lee; Stephanie Sacharow; Laura D Nations; Deqiong Ma; James M Jaworski; Ioanna Konidari; Patrice L Whitehead; Harry H Wright; Ruth K Abramson; Scott M Williams; Ramkumar Menon; Jonathan L Haines; John R Gilbert; Michael L Cuccaro; Margaret A Pericak-Vance
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

Review 9.  The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.

Authors:  Ralf Brisch; Arthur Saniotis; Rainer Wolf; Hendrik Bielau; Hans-Gert Bernstein; Johann Steiner; Bernhard Bogerts; Katharina Braun; Anna Katharina Braun; Zbigniew Jankowski; Jaliya Kumaratilake; Jaliya Kumaritlake; Maciej Henneberg; Tomasz Gos
Journal:  Front Psychiatry       Date:  2014-05-19       Impact factor: 4.157

10.  Portable Neuroimaging-Guided Noninvasive Brain Stimulation of the Cortico-Cerebello-Thalamo-Cortical Loop-Hypothesis and Theory in Cannabis Use Disorder.

Authors:  Pushpinder Walia; Abhishek Ghosh; Shubhmohan Singh; Anirban Dutta
Journal:  Brain Sci       Date:  2022-03-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.